Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
Lulu Song,1 Xiaomu Kong,2 Zhaojun Yang,1 Jinping Zhang,1 Wenying Yang,1 Bo Zhang,1 Xiaoping Chen,1 Xin Wang1 1Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 2Clinical Laboratory, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaC...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-11-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/acarbose-reduces-low-grade-albuminuria-compared-to-metformin-in-chines-peer-reviewed-fulltext-article-DMSO |
| _version_ | 1828044061706027008 |
|---|---|
| author | Song L Kong X Yang Z Zhang J Yang W Zhang B Chen X Wang X |
| author_facet | Song L Kong X Yang Z Zhang J Yang W Zhang B Chen X Wang X |
| author_sort | Song L |
| collection | DOAJ |
| description | Lulu Song,1 Xiaomu Kong,2 Zhaojun Yang,1 Jinping Zhang,1 Wenying Yang,1 Bo Zhang,1 Xiaoping Chen,1 Xin Wang1 1Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 2Clinical Laboratory, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaCorrespondence: Xin WangDepartment of Endocrinology, China-Japan Friendship Hospital, 2 Yinghua East Road, Beijing, 100029, People’s Republic of ChinaTel +86 1084205254Email xiangpian11@163.comPurpose: To assess the effect of acarbose in lowering low-grade albuminuria compared to metformin in newly diagnosed Chinese type 2 diabetes (T2DM) patients.Patients and Methods: The Metformin and AcaRbose Clinical Trial was a randomized, open-label trial in newly diagnosed T2DM patients. Participants received 48 weeks of monotherapy with acarbose (100 mg three times a day) or metformin (1500 mg once a day). As the hypoglycemic effect of acarbose and metformin has been evaluated in previous reports. This analysis studied the effect of the two antidiabetic drugs on reducing urinary albumin. The percent change in the urinary albumin/creatinine ratio (uACR) from baseline to week 48 was analyzed, and ANCOVA was employed to establish whether the effect in decreasing uACR was mediated by metabolic improvement.Results: Acarbose reduced the adjusted mean percent uACR by − 31.5% (95% confidence interval [CI] − 48.4 to − 7.5) compared with metformin. When adjusting for changes in glycated hemoglobin, body weight, systolic blood pressure and triglycerides or changes in area under the curve of glucagon-like peptide 1 (AUCGLP-1) in the standard meal test, the uACR-lowering effect was not attenuated. If stratified by eGFR, blood glucose level, sex or uACR level, the effect of acarbose versus metformin was consistent across subgroups. The proportion of patients with a reduction in uACR of at least 70% was 48.6% in the acarbose group and 34.1% in the metformin group.Conclusion: Acarbose lowered the uACR compared to metformin in newly diagnosed T2DM patients independent of improvements in hyperglycemia, blood pressure, body weight and triglycerides.Keywords: diabetes mellitus, type 2, diabetic nephropathies, hypoglycemic agents |
| first_indexed | 2024-04-10T17:50:34Z |
| format | Article |
| id | doaj.art-28d4f2b236e2467a9cffac78784ac8c9 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T17:50:34Z |
| publishDate | 2021-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-28d4f2b236e2467a9cffac78784ac8c92023-02-02T21:40:28ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072021-11-01Volume 144451445870340Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 DiabetesSong LKong XYang ZZhang JYang WZhang BChen XWang XLulu Song,1 Xiaomu Kong,2 Zhaojun Yang,1 Jinping Zhang,1 Wenying Yang,1 Bo Zhang,1 Xiaoping Chen,1 Xin Wang1 1Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 2Clinical Laboratory, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaCorrespondence: Xin WangDepartment of Endocrinology, China-Japan Friendship Hospital, 2 Yinghua East Road, Beijing, 100029, People’s Republic of ChinaTel +86 1084205254Email xiangpian11@163.comPurpose: To assess the effect of acarbose in lowering low-grade albuminuria compared to metformin in newly diagnosed Chinese type 2 diabetes (T2DM) patients.Patients and Methods: The Metformin and AcaRbose Clinical Trial was a randomized, open-label trial in newly diagnosed T2DM patients. Participants received 48 weeks of monotherapy with acarbose (100 mg three times a day) or metformin (1500 mg once a day). As the hypoglycemic effect of acarbose and metformin has been evaluated in previous reports. This analysis studied the effect of the two antidiabetic drugs on reducing urinary albumin. The percent change in the urinary albumin/creatinine ratio (uACR) from baseline to week 48 was analyzed, and ANCOVA was employed to establish whether the effect in decreasing uACR was mediated by metabolic improvement.Results: Acarbose reduced the adjusted mean percent uACR by − 31.5% (95% confidence interval [CI] − 48.4 to − 7.5) compared with metformin. When adjusting for changes in glycated hemoglobin, body weight, systolic blood pressure and triglycerides or changes in area under the curve of glucagon-like peptide 1 (AUCGLP-1) in the standard meal test, the uACR-lowering effect was not attenuated. If stratified by eGFR, blood glucose level, sex or uACR level, the effect of acarbose versus metformin was consistent across subgroups. The proportion of patients with a reduction in uACR of at least 70% was 48.6% in the acarbose group and 34.1% in the metformin group.Conclusion: Acarbose lowered the uACR compared to metformin in newly diagnosed T2DM patients independent of improvements in hyperglycemia, blood pressure, body weight and triglycerides.Keywords: diabetes mellitus, type 2, diabetic nephropathies, hypoglycemic agentshttps://www.dovepress.com/acarbose-reduces-low-grade-albuminuria-compared-to-metformin-in-chines-peer-reviewed-fulltext-article-DMSOdiabetes mellitustype 2diabetic nephropathieshypoglycemic agents |
| spellingShingle | Song L Kong X Yang Z Zhang J Yang W Zhang B Chen X Wang X Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes Diabetes, Metabolic Syndrome and Obesity diabetes mellitus type 2 diabetic nephropathies hypoglycemic agents |
| title | Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes |
| title_full | Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes |
| title_fullStr | Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes |
| title_full_unstemmed | Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes |
| title_short | Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes |
| title_sort | acarbose reduces low grade albuminuria compared to metformin in chinese patients with newly diagnosed type 2 diabetes |
| topic | diabetes mellitus type 2 diabetic nephropathies hypoglycemic agents |
| url | https://www.dovepress.com/acarbose-reduces-low-grade-albuminuria-compared-to-metformin-in-chines-peer-reviewed-fulltext-article-DMSO |
| work_keys_str_mv | AT songl acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT kongx acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT yangz acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT zhangj acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT yangw acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT zhangb acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT chenx acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes AT wangx acarbosereduceslowgradealbuminuriacomparedtometformininchinesepatientswithnewlydiagnosedtype2diabetes |